

---

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report: **September 15, 2015**

**DENTSPLY International Inc.**  
(Exact name of Registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction of incorporation)

**0-16211**  
(Commission File Number)

**39-1434669**  
(IRS Employer Identification No.)

**221 West Philadelphia Street, York, Pennsylvania 17405-0872**  
(Address of principal executive offices, including zip code)

**(717) 845-7511**  
(Registrant's telephone number, including area code)

**N/A**  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

## Item 8.01 Other Events

On September 15, 2015, DENTSPLY International Inc., a Delaware corporation (“DENTSPLY”), and Sirona Dental Systems, Inc., a Delaware corporation (“Sirona”), issued a joint press release announcing the execution of an Agreement and Plan of Merger (the “Merger Agreement”) entered into among DENTSPLY, Sirona and Dawkins Merger Sub Inc., a Delaware corporation and a direct wholly owned subsidiary of DENTSPLY, pursuant to which the companies will combine in an all-stock merger of equals. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. Upon the closing of the transaction, the name of DENTSPLY will be changed to “DENTSPLY SIRONA Inc.”. Among other things, the press release announced that, upon the closing of the transaction, the board of directors of the combined company will be comprised of 11 members, consisting of (a) six of DENTSPLY’s current directors and (b) five of Sirona’s current directors. In addition, upon completion of the transaction, Jeffrey T. Slovin, currently a director and the President and Chief Executive Officer of Sirona, will serve as a director and as Chief Executive Officer of the combined company, and Bret W. Wise, the current Chairman and Chief Executive Officer of DENTSPLY, will serve as Executive Chairman of the board of directors of the combined company. The combined company leadership team is expected to include representatives of both companies. From DENTSPLY, Christopher T. Clark and James G. Mosch are expected to serve as President and Chief Operating Officer, Technologies and President and Chief Operating Officer, Consumables, respectively. From Sirona, Ulrich Michel is expected to serve as Executive Vice President and Chief Financial Officer.

In addition, on September 15, 2015, DENTSPLY and Sirona provided supplemental information regarding the proposed transaction in connection with presentations to analysts and investors. A copy of the investor presentation is attached hereto as Exhibit 99.2 and is incorporated herein by reference.

### Forward Looking Statements

This communication, in addition to historical information, contains “forward-looking statements” (as defined in the Securities Litigation Reform Act of 1995) regarding, among other things, future events or the future financial performance of DENTSPLY and Sirona. Words such as “anticipate,” “expect,” “project,” “intend,” “believe,” and words and terms of similar substance used in connection with any discussion of future plans, actions or events identify forward-looking statements. Forward-looking statements relating to the proposed transaction include, but are not limited to: statements about the benefits of the proposed transaction between DENTSPLY and Sirona, including future financial and operating results; DENTSPLY’s and Sirona’s plans, objectives, expectations and intentions; the expected timing of completion of the proposed transaction; and other statements relating to the merger that are not historical facts. Forward-looking statements are based on information currently available to DENTSPLY and Sirona and involve estimates, expectations and projections. Investors are cautioned that all such forward-looking statements are subject to risks and uncertainties, and important factors could cause actual events or results to differ materially from those indicated by such forward-looking statements. With respect to the proposed transaction between DENTSPLY and Sirona, these factors could include, but are not limited to: the risk that DENTSPLY or Sirona may be unable to obtain governmental and regulatory approvals required for the transaction, or that required governmental and regulatory approvals may delay the transaction or result in the imposition of conditions that could reduce the anticipated benefits from the proposed transaction or cause the parties to abandon the proposed transaction; the risk that a condition to closing of the transaction may not be satisfied; the length of time necessary to consummate the proposed transaction, which may be longer than anticipated for various reasons; the risk that the businesses will not be integrated successfully; the risk that the cost savings, synergies and growth from the proposed transaction may not be fully realized or may take longer to realize than expected; the diversion of management time on transaction-related issues; the effect of future regulatory or legislative actions on the companies or the industries in which they operate; the risk that the credit ratings of the combined company or its subsidiaries may be different from what the companies expect; economic and foreign exchange rate volatility; the continued strength of the dental and medical device markets; unexpected changes relating to competitive factors in the dental and medical devices industries; the timing, success and market reception for DENTSPLY’s and Sirona’s new and existing products; the possibility of new technologies outdating DENTSPLY’s or Sirona’s products; the outcomes of any litigation; continued support of DENTSPLY’s or Sirona’s products by influential dental and medical professionals; changes in the general economic environment, or social or political conditions, that could affect the businesses; the potential impact of the announcement or consummation of the proposed transaction on relationships with customers, suppliers, competitors, management and other employees; the ability to attract new customers and retain existing customers in the manner anticipated; the ability to hire and retain key personnel; reliance on and integration of information technology systems; the risks associated with assumptions the parties make in connection with the parties’ critical accounting estimates and legal proceedings; and the potential of international unrest, economic downturn or effects of currencies, tax assessments, tax adjustments, anticipated tax rates, raw material costs or availability, benefit or retirement plan costs, or other regulatory compliance costs.

---

Additional information concerning other risk factors is also contained in DENTSPLY's and Sirona's most recently filed Annual Reports on Form 10-K, subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other SEC filings.

Many of these risks, uncertainties and assumptions are beyond DENTSPLY's or Sirona's ability to control or predict. Because of these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements. Furthermore, forward-looking statements speak only as of the information currently available to the parties on the date they are made, and neither DENTSPLY nor Sirona undertakes any obligation to update publicly or revise any forward-looking statements to reflect events or circumstances that may arise after the date of this communication. Nothing in this communication is intended, or is to be construed, as a profit forecast or to be interpreted to mean that earnings per DENTSPLY share or Sirona share for the current or any future financial years or those of the combined company, will necessarily match or exceed the historical published earnings per DENTSPLY share or Sirona share, as applicable. Neither DENTSPLY nor Sirona gives any assurance (1) that either DENTSPLY or Sirona will achieve its expectations, or (2) concerning any result or the timing thereof, in each case, with respect to any regulatory action, administrative proceedings, government investigations, litigation, warning letters, consent decree, cost reductions, business strategies, earnings or revenue trends or future financial results. All subsequent written and oral forward-looking statements concerning DENTSPLY, Sirona, the proposed transaction, the combined company or other matters and attributable to DENTSPLY or Sirona or any person acting on their behalf are expressly qualified in their entirety by the cautionary statements above.

#### **Additional Information And Where To Find It**

This communication is for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval with respect to the proposed transaction between DENTSPLY and Sirona or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended. The proposed business combination transaction between DENTSPLY and Sirona will be submitted to the respective stockholders of DENTSPLY and Sirona for their consideration. DENTSPLY will file with the Securities and Exchange Commission (the "SEC") a registration statement on Form S-4 that will include a joint proxy statement of DENTSPLY and Sirona that also constitutes a prospectus of DENTSPLY. DENTSPLY and Sirona will deliver the joint proxy statement/prospectus to their respective stockholders as required by applicable law. DENTSPLY and Sirona also plan to file other documents with the SEC regarding the proposed transaction. This communication is not a substitute for any prospectus, proxy statement or any other document which DENTSPLY or Sirona may file with the SEC in connection with the proposed transaction. **INVESTORS AND SECURITY HOLDERS OF DENTSPLY AND SIRONA ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS THAT WILL BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT DENTSPLY, SIRONA, THE PROPOSED TRANSACTION AND RELATED MATTERS.** Investors and stockholders will be able to obtain free copies of the joint proxy statement/prospectus and other documents containing important information about DENTSPLY and Sirona, once such documents are filed with the SEC, through the website maintained by the SEC at [www.sec.gov](http://www.sec.gov). DENTSPLY and Sirona make available free of charge at [www.sirona.com](http://www.sirona.com) and [www.dentsply.com](http://www.dentsply.com), respectively (in the "Investor Relations" section), copies of materials they file with, or furnish to, the SEC.

#### **Participants In The Merger Solicitation**

DENTSPLY, Sirona, and certain of their respective directors, executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies from the stockholders of DENTSPLY and Sirona in connection with the proposed transaction. Information about the directors and executive officers of Sirona is set forth in its proxy statement for its 2014 annual meeting of stockholders, which was filed with the SEC on January 28, 2015. Information about the directors and executive officers of DENTSPLY is set forth in its proxy statement for its 2015 annual meeting of stockholders, which was filed with the SEC on April 10, 2015. These documents can be obtained free of charge from the sources indicated above. Other information regarding those persons who are, under the rules of the SEC, participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the joint proxy statement/prospectus and other relevant materials to be filed with the SEC when they become available.

---

**Item 9.01 Financial Statements and Exhibits**

## (d) Exhibits

<u>Exhibit Number</u>	<u>Description of Exhibit</u>
99.1	Joint Press Release of DENTSPLY International Inc. and Sirona Dental Systems, Inc., issued September 15, 2015
99.2	Investor Presentation, dated September 15, 2015

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**DENTSPLY International Inc.**

Date: September 15, 2015

By: /s/ Christopher T. Clark  
President and  
Chief Financial Officer

---

**EXHIBIT INDEX**

Exhibit Number	Description of Exhibit
99.1	Joint Press Release of DENTSPLY International Inc. and Sirona Dental Systems, Inc., issued September 15, 2015
99.2	Investor Presentation, dated September 15, 2015

FOR IMMEDIATE RELEASE



**DENTSPLY and Sirona Announce Combination to Create The Dental Solutions Company in \$13 Billion Merger of Equals**

- **Combination of Leading Platforms in Consumables, Equipment and Technology Creates Complementary End-to-End Solutions to Meet Customer Needs and Improve Patient Care**
- **Better Positioned to Capitalize on Key Industry Trends to Drive Growth, Including Accelerating Adoption of Digital Dentistry**
- **Attractive Financial Profile with Robust Cash Flow for Growth Reinvestments and Return of Capital to Shareholders**
- **Transaction Expected to Result in Annual Pre-Tax Synergies of \$125+ Million and be Accretive to Adjusted Earnings per Share for Shareholders of Both Companies within the First Year**

YORK, PA & LONG ISLAND CITY, NY, September 15, 2015 – DENTSPLY International Inc. (“DENTSPLY”) (NASDAQ: XRAY) and Sirona Dental Systems Inc. (“Sirona”) (NASDAQ: SIRO) today announced that the Boards of Directors of both companies have unanimously approved a definitive merger agreement under which the companies will combine in an all-stock merger of equals. The transaction will result in the world’s largest manufacturer of professional dental products and technologies with an implied pro forma equity value of approximately \$13.3 billion, based on the closing prices of DENTSPLY and Sirona on September 14, 2015. The new company will have net revenue of approximately \$3.8 billion and adjusted EBITDA of more than \$900 million on a pro forma basis for the last twelve months.

The combined company, supported by its leading platforms in consumables, equipment and technology, will offer a powerful set of complementary offerings and end-to-end solutions to enhance patient care. Customers across the globe will be supported by the largest sales and service infrastructure in the industry to deliver an optimized product range that will meet the increasing global demand for digital dentistry and integrated solutions. The combined company will have a strong, flexible balance sheet and significant cash flow, giving it the ability to accelerate growth and deliver attractive returns for shareholders.

Under the terms of the agreement, Sirona shareholders will receive 1.8142 shares of DENTSPLY for each existing Sirona share. The exchange ratio reflects an “at market” combination based upon the 20 and 30 day average volume weighted trading prices for each company. Upon closing of the transaction, DENTSPLY shareholders will own 58% and Sirona shareholders will own 42% of the combined company. The stock issuance in the merger is expected to be tax-free to shareholders of both companies.

---

## Proven Leadership Team

Upon closing of the transaction, Jeffrey T. Slovin, President and Chief Executive Officer of Sirona, will serve as Chief Executive Officer of the combined company and will be a member of the Board of Directors. Bret. W. Wise, Chairman and Chief Executive Officer of DENTSPLY, will serve as Executive Chairman of the combined company. The Executive Chairman will work in collaboration with the CEO to execute the corporate strategy and to integrate the companies and cultures. From DENTSPLY, Christopher T. Clark and James G. Mosch will serve as President and Chief Operating Officer, Technologies and President and Chief Operating Officer, Dental and Healthcare Consumables, respectively. From Sirona, Ulrich Michel will serve as Executive Vice President and Chief Financial Officer. The Board of Directors will consist of 11 members, six of which (including Mr. Wise) are current DENTSPLY directors and five of which (including Mr. Slovin) are current Sirona directors. Additional senior leadership positions at the combined company will be named at a later date, consisting of representatives from both companies.

The combined company will be called DENTSPLY SIRONA and trade on the NASDAQ under the symbol XRAY. DENTSPLY SIRONA's Global headquarters will be located in York, PA, the location of DENTSPLY's current headquarters, while the International headquarters will be located in Salzburg, Austria.

Jeffrey T. Slovin, President and Chief Executive Officer of Sirona said, "This is an exciting day for both companies, for the dental community and for patients around the globe. We are bringing together two world class companies that share a culture of innovation and will foster the development of differentiated, integrated solutions for general practitioners and specialists, particularly in the highest growth segments of the dental industry. Combining Sirona's proven digital solutions and equipment with DENTSPLY's leading consumables platform creates the most comprehensive dental solutions offering available to meet customer demand in every key segment. I look forward to leading the talented teams of both Sirona and DENTSPLY as we drive the global digitization of dentistry, offer superior solutions to customers and patients and create The Dental Solutions Company."

"We are excited about bringing together two industry leaders," said Bret W. Wise, Chairman and Chief Executive Officer of DENTSPLY. "DENTSPLY SIRONA will offer a comprehensive line of solutions to more effectively meet the needs of dental customers all over the world and advance patient care. With a strong financial profile, comprehensive product offerings and integrated solutions, DENTSPLY SIRONA will be uniquely positioned to deliver attractive returns for our shareholders and make dentistry better, faster and safer around the world. I look forward to working with Jeff and the combined management team to deliver on this mission."

## Compelling Strategic and Financial Benefits

The proposed transaction will create the world's largest manufacturer of professional dental products and technologies with scale and breadth across all major geographies and competitive offerings in each of the major dental categories. Specific benefits include:

- **Increased Scale and Product Breadth:** The combination will result in a company with net revenue of approximately \$3.8 billion and adjusted EBITDA of more than \$900 million, excluding the incremental benefit of synergies. The combined company will have the industry's largest sales and service infrastructure, supported by leading distributors. DENTSPLY SIRONA will also be positioned to provide market-leading solutions in every major dental category across consumables, specialties and equipment on a global basis.
-

- **Total Solutions Provider:** With consumables, equipment and technology under one roof, the new company will be able to deliver digital technologies and integrated solutions and workflows to enhance efficiency and patient care for general practitioners and specialists.
- **Strong Commitment to Innovation:** The combined company will have an enhanced commitment to innovation in consumables, equipment and technology. By leveraging both companies' significant R&D capabilities across DENTSPLY's world-class materials science expertise and Sirona's industry-leading technology platform, the broadened product offering will support the combined company's position as a leading innovator in the dental market. DENTSPLY SIRONA will have over 600 scientists and R&D staff working to accelerate the development of new, better, safer and more efficient dental solutions and procedures.
- **Financial Strength and Flexibility:** The combined company will enjoy an attractive financial profile with robust cash flow for continued growth reinvestments and a focus on returning capital to shareholders. DENTSPLY SIRONA intends to execute a \$500 million share buyback as soon as possible after closing to drive incremental shareholder value. The new company plans to maintain DENTSPLY's current dividend level of \$0.29 per share.
- **Substantial Synergies:** The combination of DENTSPLY and Sirona is expected to deliver \$125+ million of annual pre-tax synergies by the third year following the completion of the transaction. The new company plans to achieve meaningful cost and revenue synergies by capitalizing on a broadened product offering, expanded customer base and scalable infrastructure. The combination is expected to unlock significant shareholder value and be accretive to each company's shareholders on an adjusted earnings per share basis within the first year.
- **Experienced Management Team:** The combined company will be led by the most experienced management team in the dental industry, with strong track records of growth and leadership in developing differentiated global product offerings. The DENTSPLY and Sirona teams have a successful history of collaboration in a number of product categories, providing a strong foundation for the combined management team to accelerate growth.

## Approvals

The transaction, which is expected to be completed in the first quarter of calendar 2016, is subject to the receipt of regulatory approvals and other customary closing conditions. The transaction requires the approval of shareholders of both DENTSPLY and Sirona.

## Advisors

Moelis & Company LLC is serving as exclusive financial advisor to DENTSPLY, and Skadden, Arps, Slate, Meagher & Flom LLP is serving as its legal advisor. Jefferies LLC is serving as exclusive financial advisor to Sirona, and Latham & Watkins LLP is serving as its legal advisor.

---

## Conference Call and Webcast

The companies will hold a joint conference call and webcast today at 5:30 pm ET to discuss this announcement followed by a question and answer session. The conference call can be accessed by dialing (866) 610-1072 within the U.S. and (973) 935-2840 for all other locations. The live webcast will be available to interested parties via DENTSPLY's IR website at [www.investor.dentsply.com](http://www.investor.dentsply.com) and Sirona's IR website at [www.sirona.com/en/investors](http://www.sirona.com/en/investors). A presentation will accompany the conference call. These slides may be accessed on the DENTSPLY and Sirona websites. A replay of the webcast will be available for two weeks following the call. To access the replay, please dial (800) 585-8367 within the U.S. or (404) 537-3406 for all other locations. The Conference ID for the conference call and replay is 41327193.

## About DENTSPLY

DENTSPLY International Inc. is a leading manufacturer and distributor of dental and other consumable medical device products. The Company believes it is the world's largest manufacturer of consumable dental products for the professional dental market. For over a century, DENTSPLY's commitment to innovation and professional collaboration has enhanced its portfolio of branded consumables and small equipment. Headquartered in the United States, the Company has global operations with sales in more than 120 countries. Visit [www.dentsply.com](http://www.dentsply.com) for more information about DENTSPLY and its products.

## About Sirona

Sirona, the dental technology leader, has served dealers and dentists worldwide for more than 130 years. Sirona develops, manufactures, and markets a complete line of dental products, including CAD/CAM restoration systems (CEREC), digital intra-oral, panoramic and 3D imaging systems, dental treatment centers and handpieces. Visit [www.sirona.com](http://www.sirona.com) for more information about Sirona and its products.

## Forward-Looking Statements

This communication, in addition to historical information, contains "forward-looking statements" (as defined in the Securities Litigation Reform Act of 1995) regarding, among other things, future events or the future financial performance of DENTSPLY and Sirona. Words such as "anticipate," "expect," "project," "intend," "believe," and words and terms of similar substance used in connection with any discussion of future plans, actions or events identify forward-looking statements. Forward-looking statements relating to the proposed transaction include, but are not limited to: statements about the benefits of the proposed transaction between DENTSPLY and Sirona, including future financial and operating results; DENTSPLY's and Sirona's plans, objectives, expectations and intentions; the expected timing of completion of the proposed transaction; and other statements relating to the merger that are not historical facts. Forward-looking statements are based on information currently available to DENTSPLY and Sirona and involve estimates, expectations and projections. Investors are cautioned that all such forward-looking statements are subject to risks and uncertainties, and important factors could cause actual events or results to differ materially from those indicated by such forward-looking statements. With respect to the proposed transaction between DENTSPLY and Sirona, these factors could include, but are not limited to: the risk that DENTSPLY or Sirona may be unable to obtain governmental and regulatory approvals required for the transaction, or that required governmental and regulatory approvals may delay the transaction or result in the imposition of conditions that could reduce the anticipated benefits from the proposed transaction or cause the parties to abandon the proposed transaction; the risk that a condition to closing of the transaction may not be satisfied; the length of time necessary to consummate the proposed transaction, which may be longer than anticipated for various reasons; the risk that the businesses will not be integrated successfully; the risk that the cost savings, synergies and growth from the proposed transaction may not be fully realized or may take longer to realize than expected; the diversion of management time on transaction-related issues; the effect of future regulatory or legislative actions on the companies or the industries in which they operate; the risk that the credit ratings of the combined company or its subsidiaries may be different from what the companies expect; economic and foreign exchange rate volatility; the continued strength of the dental and medical device markets; unexpected changes relating to competitive factors in the dental and medical devices industries; the timing, success and market reception for DENTSPLY's and Sirona's new and existing products; the possibility of new technologies outdating DENTSPLY's or Sirona's products; the outcomes of any litigation; continued support of DENTSPLY's or Sirona's products by influential dental and medical professionals; changes in the general economic environment, or social or political conditions, that could affect the businesses; the potential impact of the announcement or consummation of the proposed transaction on relationships with customers, suppliers, competitors, management and other employees; the ability to attract new customers and retain existing customers in the manner anticipated; the ability to hire and retain key personnel; reliance on and integration of information technology systems; the risks associated with assumptions the parties make in connection with the parties' critical accounting estimates and legal proceedings; and the potential of international unrest, economic downturn or effects of currencies, tax assessments, tax adjustments, anticipated tax rates, raw material costs or availability, benefit or retirement plan costs, or other regulatory compliance costs.

---

Additional information concerning other risk factors is also contained in DENTSPLY's and Sirona's most recently filed Annual Reports on Form 10-K, subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other SEC filings.

Many of these risks, uncertainties and assumptions are beyond DENTSPLY's or Sirona's ability to control or predict. Because of these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements. Furthermore, forward-looking statements speak only as of the information currently available to the parties on the date they are made, and neither DENTSPLY nor Sirona undertakes any obligation to update publicly or revise any forward-looking statements to reflect events or circumstances that may arise after the date of this communication. Nothing in this communication is intended, or is to be construed, as a profit forecast or to be interpreted to mean that earnings per DENTSPLY share or Sirona share for the current or any future financial years or those of the combined company, will necessarily match or exceed the historical published earnings per DENTSPLY share or Sirona share, as applicable. Neither DENTSPLY nor Sirona gives any assurance (1) that either DENTSPLY or Sirona will achieve its expectations, or (2) concerning any result or the timing thereof, in each case, with respect to any regulatory action, administrative proceedings, government investigations, litigation, warning letters, consent decree, cost reductions, business strategies, earnings or revenue trends or future financial results. All subsequent written and oral forward-looking statements concerning DENTSPLY, Sirona, the proposed transaction, the combined company or other matters and attributable to DENTSPLY or Sirona or any person acting on their behalf are expressly qualified in their entirety by the cautionary statements above.

---

### **Additional Information and Where to Find It**

This communication is for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval with respect to the proposed transaction between DENTSPLY and Sirona or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended. The proposed business combination transaction between DENTSPLY and Sirona will be submitted to the respective stockholders of DENTSPLY and Sirona for their consideration. DENTSPLY will file with the Securities and Exchange Commission (the "SEC") a registration statement on Form S-4 that will include a joint proxy statement of DENTSPLY and Sirona that also constitutes a prospectus of DENTSPLY. DENTSPLY and Sirona will deliver the joint proxy statement/prospectus to their respective stockholders as required by applicable law. DENTSPLY and Sirona also plan to file other documents with the SEC regarding the proposed transaction. This communication is not a substitute for any prospectus, proxy statement or any other document which DENTSPLY or Sirona may file with the SEC in connection with the proposed transaction. **INVESTORS AND SECURITY HOLDERS OF DENTSPLY AND SIRONA ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS THAT WILL BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT DENTSPLY, SIRONA, THE PROPOSED TRANSACTION AND RELATED MATTERS.** Investors and stockholders will be able to obtain free copies of the joint proxy statement/prospectus and other documents containing important information about DENTSPLY and Sirona, once such documents are filed with the SEC, through the website maintained by the SEC at [www.sec.gov](http://www.sec.gov). DENTSPLY and Sirona make available free of charge at [www.dentsply.com](http://www.dentsply.com) and [www.sirona.com](http://www.sirona.com), respectively (in the "Investor Relations" section), copies of materials they file with, or furnish to, the SEC.

### **Participants in the Merger Solicitation**

DENTSPLY, Sirona, and certain of their respective directors, executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies from the stockholders of DENTSPLY and Sirona in connection with the proposed transaction. Information about the directors and executive officers of Sirona is set forth in its proxy statement for its 2014 annual meeting of stockholders, which was filed with the SEC on January 28, 2015. Information about the directors and executive officers of DENTSPLY is set forth in its proxy statement for its 2015 annual meeting of stockholders, which was filed with the SEC on April 10, 2015. These documents can be obtained free of charge from the sources indicated above. Other information regarding those persons who are, under the rules of the SEC, participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the joint proxy statement/prospectus and other relevant materials to be filed with the SEC when they become available.

---

## **Contacts**

### **DENTSPLY**

#### **Investors:**

Derek Leckow

*VP, Investor Relations*

DENTSPLY International Inc.

Tel: +1 (717) 849-7863

E-mail: derek.leckow@dentsply.com

#### **Media:**

Michael Freitag / Tim Lynch

*Partner / Partner*

Joele Frank

Tel: +1 (212) 355-4449

E-mail: mfreitag@joelefrank.com or tlynch@joelefrank.com

### **Sirona**

#### **Investors:**

Joshua Zable

*VP, Investor Relations*

Sirona Dental Systems Inc.

Tel: +1 (718) 482-2184

E-mail: joshua.zable@sirona.com

#### **Media:**

Chuck Dohrenwend

*Managing Director*

Abernathy MacGregor Group

Tel: +1 (212) 371-5999

E-mail: cod@abmac.com

---



---

# Better Dentistry Together

Creating The Dental Solutions Company

---

September 2015

---

**Forward-Looking Statements**

This communication, in addition to historical information, contains "forward-looking statements" (as defined in the Securities Litigation Reform Act of 1995) regarding, among other things, future events or the future financial performance of DENTSPLY International Inc. ("DENTSPLY") and Sirona Dental Systems Inc. ("Sirona"). Words such as "anticipate," "expect," "project," "intend," "believe," and words and terms of similar substance used in connection with any discussion of future plans, actions or events identify forward-looking statements. Forward-looking statements relating to the proposed transaction include, but are not limited to: statements about the benefits of the proposed transaction between DENTSPLY and Sirona, including future financial and operating results; DENTSPLY's and Sirona's plans, objectives, expectations and intentions; the expected timing of completion of the proposed transaction; and other statements relating to the merger that are not historical facts. Forward-looking statements are based on information currently available to DENTSPLY and Sirona and involve estimates, expectations and projections. Investors are cautioned that all such forward-looking statements are subject to risks and uncertainties, and important factors could cause actual events or results to differ materially from those indicated by such forward-looking statements. With respect to the proposed transaction between DENTSPLY and Sirona, these factors could include, but are not limited to: the risk that DENTSPLY or Sirona may be unable to obtain governmental and regulatory approvals required for the transaction, or that required governmental and regulatory approvals may delay the transaction or result in the imposition of conditions that could reduce the anticipated benefits from the proposed transaction or cause the parties to abandon the proposed transaction; the risk that a condition to closing of the transaction may not be satisfied; the length of time necessary to consummate the proposed transaction, which may be longer than anticipated for various reasons; the risk that the businesses will not be integrated successfully; the risk that the cost savings, synergies and growth from the proposed transaction may not be fully realized or may take longer to realize than expected; the diversion of management time on transaction-related issues; the effect of future regulatory or legislative actions on the companies or the industries in which they operate; the risk that the credit ratings of the combined company or its subsidiaries may be different from what the companies expect; economic and foreign exchange rate volatility; the continued strength of the dental and medical device markets; unexpected changes relating to competitive factors in the dental and medical devices industries; the timing, success and market reception for DENTSPLY's and Sirona's new and existing products; the possibility of new technologies outdating DENTSPLY's or Sirona's products; the outcomes of any litigation; continued support of DENTSPLY's or Sirona's products by influential dental and medical professionals; changes in the general economic environment, or social or political conditions, that could affect the businesses; the potential impact of the announcement or consummation of the proposed transaction on relationships with customers, suppliers, competitors, management and other employees; the ability to attract new customers and retain existing customers in the manner anticipated; the ability to hire and retain key personnel; reliance on and integration of information technology systems; the risks associated with assumptions the parties make in connection with the parties' critical accounting estimates and legal proceedings; and the potential of international unrest, economic downturn or effects of currencies, tax assessments, tax adjustments, anticipated tax rates, raw material costs or availability, benefit or retirement plan costs, or other regulatory compliance costs.

Additional information concerning other risk factors is also contained in DENTSPLY's and Sirona's most recently filed Annual Reports on Form 10-K, subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other SEC filings.

Many of these risks, uncertainties and assumptions are beyond DENTSPLY's or Sirona's ability to control or predict. Because of these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements. Furthermore, forward-looking statements speak only as of the information currently available to the parties on the date they are made, and neither DENTSPLY nor Sirona undertakes any obligation to update publicly or revise any forward-looking statements to reflect events or circumstances that may arise after the date of this communication. Nothing in this communication is intended, or is to be construed, as a profit forecast or to be interpreted to mean that earnings per DENTSPLY share or Sirona share for the current or any future financial years or those of the combined company, will necessarily match or exceed the historical published earnings per DENTSPLY share or Sirona share, as applicable. Neither DENTSPLY nor Sirona gives any assurance (1) that either DENTSPLY or Sirona will achieve its expectations, or (2) concerning any result or the timing thereof, in each case, with respect to any regulatory action, administrative proceedings, government investigations, litigation, warning letters, consent decrees, cost reductions, business strategies, earnings or revenue trends or future financial results. All subsequent written and oral forward-looking statements concerning DENTSPLY, Sirona, the proposed transaction, the combined company or other matters and attributable to DENTSPLY or Sirona or any person acting on their behalf are expressly qualified in their entirety by the cautionary statements above.

**Additional Information And Where To Find It**

This communication is for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval with respect to the proposed transaction between DENTSPLY and Sirona or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended. The proposed business combination transaction between DENTSPLY and Sirona will be submitted to the respective stockholders of DENTSPLY and Sirona for their consideration. DENTSPLY will file with the Securities and Exchange Commission (the "SEC") a registration statement on Form S-4 that will include a joint proxy statement of DENTSPLY and Sirona that also constitutes a prospectus of DENTSPLY. DENTSPLY and Sirona will deliver the joint proxy statement/prospectus to their respective stockholders as required by applicable law. DENTSPLY and Sirona also plan to file other documents with the SEC regarding the proposed transaction. This communication is not a substitute for any prospectus, proxy statement or any other document which DENTSPLY or Sirona may file with the SEC in connection with the proposed transaction. **INVESTORS AND SECURITY HOLDERS OF DENTSPLY AND SIRONA ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS THAT WILL BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT DENTSPLY, SIRONA, THE PROPOSED TRANSACTION AND RELATED MATTERS.** Investors and stockholders will be able to obtain free copies of the joint proxy statement/prospectus and other documents containing important information about DENTSPLY and Sirona, once such documents are filed with the SEC, through the website maintained by the SEC at [www.sec.gov](http://www.sec.gov). DENTSPLY and Sirona make available free of charge at [www.dentsply.com](http://www.dentsply.com) and [www.sirona.com](http://www.sirona.com), respectively (in the "Investor Relations" section), copies of materials they file with, or furnish to, the SEC.

**Participants In The Merger Solicitation**

DENTSPLY, Sirona, and certain of their respective directors, executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies from the stockholders of DENTSPLY and Sirona in connection with the proposed transaction. Information about the directors and executive officers of Sirona is set forth in its proxy statement for its 2014 annual meeting of stockholders, which was filed with the SEC on January 28, 2015. Information about the directors and executive officers of DENTSPLY is set forth in its proxy statement for its 2015 annual meeting of stockholders, which was filed with the SEC on April 10, 2015. These documents can be obtained free of charge from the sources indicated above. Other information regarding those persons who are, under the rules of the SEC, participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the joint proxy statement/prospectus and other relevant materials to be filed with the SEC when they become available.



*Combined Net Revenue of ~\$3.8bn<sup>1</sup> and Adjusted EBITDA of >\$900mm<sup>1</sup>*

- **Creates the largest global manufacturer of professional dental products and technologies with a world-class sales and service infrastructure**
- **Combination of leading platforms in consumables, equipment and technology creates complementary end-to-end solutions to meet customer needs**
- **Strong culture of innovation and enhanced R&D capabilities will drive the development of better, faster and safer solutions to advance patient care**
- **Better positioned to capitalize on key industry trends to drive growth**
- **\$125+ million of annual pre-tax synergies by year 3, driving robust cash flow for growth reinvestments and return of capital to shareholders**
- **Accretive to both sets of shareholders within the first year**

(1) LTM statistics as of 6/30/15 and excludes revenue from precious metals

<p>Structure and Exchange Ratio</p>	<ul style="list-style-type: none"> <li>▪ Stock-for-stock merger of equals</li> <li>▪ Sirona shareholders receive 1.8142 DENTSPLY shares for each existing Sirona share</li> <li>▪ \$500 million share buyback to be executed as soon as possible post-close</li> </ul>
<p>Ownership</p>	<ul style="list-style-type: none"> <li>▪ DENTSPLY shareholders: 58%</li> <li>▪ Sirona shareholders: 42%</li> </ul>
<p>Governance</p>	<ul style="list-style-type: none"> <li>▪ Executive Chairman: Bret W. Wise (DENTSPLY)</li> <li>▪ Chief Executive Officer: Jeffrey T. Slovin (Sirona)</li> <li>▪ President and Chief Operating Officer, Technologies: Christopher T. Clark (DENTSPLY)</li> <li>▪ President and Chief Operating Officer, Dental and Healthcare Consumables: James G. Mosch (DENTSPLY)</li> <li>▪ Executive Vice President and Chief Financial Officer: Ulrich Michel (Sirona)</li> <li>▪ Board: 11 members (6 directors from DENTSPLY Board and 5 directors from Sirona Board)</li> </ul>
<p>Name / Ticker / Headquarters</p>	<ul style="list-style-type: none"> <li>▪ Company name: DENTSPLY SIRONA</li> <li>▪ Ticker: XRAY (NASDAQ)</li> <li>▪ Global Headquarters: York, PA; International Headquarters: Salzburg, Austria</li> </ul>
<p>Conditions / Timing</p>	<ul style="list-style-type: none"> <li>▪ DENTSPLY and Sirona shareholder approval</li> <li>▪ Regulatory approvals and other customary closing conditions</li> <li>▪ Expected closing: 1st Quarter of Calendar Year 2016</li> </ul>

	DENTSPLY	Sirona
<b>Headquarters</b>	York, PA	Long Island City, NY
<b>Employees</b>	11,600	3,500
<b>Market Cap (as of 9/14/15)</b>	\$7.7bn	\$5.6bn
<b>Revenue<sup>1</sup> (LTM 6/30/15)</b>	\$2.7bn	\$1.1bn
<b>Adj. EBITDA (LTM 6/30/15)</b>	\$588mm	\$323mm
<b>Highlights</b>	<ul style="list-style-type: none"> <li>✓ <b>Leader in dental consumables</b> <ul style="list-style-type: none"> <li>– Broadest portfolio in the global consumables market</li> <li>– Driving dental best practices for over a century</li> </ul> </li> <li>✓ <b>Focus on innovation and education</b> <ul style="list-style-type: none"> <li>– R&amp;D: Over 50 clinical studies ongoing</li> <li>– 30+ significant new products annually</li> <li>– Training over 300,000 dentists per year</li> <li>– Over 2,500 patents</li> </ul> </li> <li>✓ <b>Positioned for growth</b> <ul style="list-style-type: none"> <li>– Leader in high growth specialties</li> <li>– M&amp;A competency: 25 transactions since 2000</li> </ul> </li> <li>✓ <b>Global deployment</b> <ul style="list-style-type: none"> <li>– Large, 3,500 member sales team in distributed and direct channels serving an est. 600k dentists worldwide</li> <li>– Sales in more than 120 countries</li> <li>– Infrastructure in more than 40 countries</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>✓ <b>Leader in dental technology and equipment</b> <ul style="list-style-type: none"> <li>– Leader in CAD/CAM and imaging</li> <li>– Over 130 year track record of innovation</li> </ul> </li> <li>✓ <b>“The Innovator” in dental technology</b> <ul style="list-style-type: none"> <li>– ~300 engineers and scientists</li> <li>– Introduced many “firsts” to dental technology</li> <li>– Dental academy and institutional training focus</li> </ul> </li> <li>✓ <b>Driving major growth trends</b> <ul style="list-style-type: none"> <li>– Digital dentistry</li> <li>– Single-visit dentistry</li> <li>– Expanding treatment modalities for GPs</li> </ul> </li> <li>✓ <b>Leading global sales and service infrastructure</b> <ul style="list-style-type: none"> <li>– Largest sales and service network for dental equipment and technology to support customers globally</li> <li>– Sales in more than 120 countries</li> <li>– 29 locations worldwide</li> </ul> </li> </ul>


(1) DENTSPLY revenue excludes precious metals

## Dental Market Overview

- **Dental is an attractive, growing global market**
  - Favorable demographics – an aging population driving demand for specialties, prosthetics, restorative and aesthetic dentistry
  - Focus on preventive dental care supports retention of natural teeth into old age
  - Aesthetic dentistry increasing in popularity
  - Large private pay component, less exposure to reimbursement changes
  - Market typically grows 1-2x GDP
- **Emerging markets demanding higher quality dentistry**
  - ~80% of global population; ~5.5 billion people
  - Growing middle class
  - Access to dental care improving
- **Accelerating adoption of digital technologies**
- **Demand for efficiency driving need for integrated solutions**

## Global Dental Market

~\$21 billion market




## Creating THE Dental Solutions Company

(LTM as of 6/30/15)


Significant Scale with ~\$4Bn of Revenue

DENTSPLY	Sirona	Combined Business
\$2.7Bn <sup>1</sup>	\$1.1Bn	\$3.8Bn <sup>1</sup>

Complementary Product Offerings



Geographically Balanced



Enhanced Sales and Service

**Creates the industry's leading education, sales and service infrastructure globally, supported by strong distribution relationships**

**Bringing Scale and Product Breadth to Customers on a Global Basis**

(1) DENTSPLY revenue excludes precious metals

Consumables			Specialties			Equipment			
Preventive	Restorative	Prosthetics	Endodontics	Implants	Orthodontic	CAD / CAM	Imaging	Treatment Centers	Instruments
<b>Strong Position</b>									
✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
<b>Well-Established Brands</b>									

**Broadened Range of Products and Solutions to Better Serve Customers**

### Innovation in Equipment

- >300 engineers and scientists
- 5-6% of sales dedicated annually
- >250 scientific studies and 30 years of clinical data on CAD/CAM
- >850 patents and patent applications
- Consistent and sequenced new product introductions

### Innovation in Consumables

- ~30 major new products launched each year
- Significant collaboration with opinion leaders via 10,000+ clinical programs annually
- >50 clinical studies ongoing, thousands of clinical studies supporting existing brands
- >2,500 patents
- Focused on improving clinical outcomes

### Enhanced R&D Capabilities to Drive Sustainable Long-Term Growth

- **Leading R&D platform with >600 engineers and scientists**
- **Robust combined clinical education platform to bolster innovation and accelerate adoption of new technologies and solutions**
- **Enhanced capabilities to foster the development of new, safer, better and more efficient dental solutions and procedures**

### Changing Industry Dynamics

Accelerating adoption of CAD/CAM, 3D imaging and digital solutions

General practitioners taking on more specialized procedures requiring advanced technologies

Patients demanding better, faster and safer dentistry

Integrated solutions and workflows driven by increased focus on dentist productivity and efficiency

Growing demand for dentistry in developed and developing markets

### Combination Benefits

- ✓ **Leader in digital technologies and solutions**
  - Complementary offering of chairside restorative workflow
  - Digital technologies to plan and place implants and custom abutments
  - More efficient, digital orthodontic workflow
  - Digital highway connecting dentists to labs and specialists
- ✓ **Enabling single-visit dentistry**
  - Reduced chair time
  - Better aesthetics, better patient experience, better outcomes
- ✓ **Increases dental practice efficiency**
- ✓ **Global infrastructure to execute on evolving trends**

**Optimized Offerings to Accelerate Digital Trends and Drive Adoption of Integrated Solutions to Create Better, Faster and Safer Dentistry**

## Compelling Strategic Rationale

Increased scale, product breadth  
and global reach

World-class sales  
and customer service infrastructure

Digital technologies, integrated solutions  
and optimized workflow

Commitment to innovation  
and enhanced R&D capabilities

## Enabling Better Dentistry

- **Improving solutions for dental practitioners**
  - Faster technologies and workflow solutions
  - Better integrated product offering
  - Larger sales and service infrastructure
  - More innovation
  - Increased efficiency to drive dental practices
- **Advancing patient care**
  - Shorter and fewer visits
  - Safer procedures with stronger diagnostic tools
  - Improved clinical outcomes

<b>Enhancing Growth</b>	<b>Differentiated, Integrated Solutions</b>	<ul style="list-style-type: none"> <li>▪ End-to-end solutions across treatment modalities</li> </ul>
	<b>Expansion of Product Suite</b>	<ul style="list-style-type: none"> <li>▪ Provide complementary product solutions to a broader customer base</li> </ul>
	<b>Cross-selling Opportunities</b>	<ul style="list-style-type: none"> <li>▪ Significant installed base across combined customers</li> </ul>
<b>Optimizing Infrastructure</b>	<b>Manufacturing Efficiencies</b>	<ul style="list-style-type: none"> <li>▪ Consolidate manufacturing footprint and improve overhead utilization</li> </ul>
	<b>Logistics / Procurement</b>	<ul style="list-style-type: none"> <li>▪ Logistics and supply chain optimization / purchasing efficiencies</li> </ul>
	<b>Corporate Savings</b>	<ul style="list-style-type: none"> <li>▪ Corporate consolidation and optimization</li> </ul>
<b>Upside Opportunities</b>		<ul style="list-style-type: none"> <li>▪ Capital structure efficiency</li> </ul>
<b>Combination Unlocks Significant Value</b>		

- Accretive to both sets of shareholders within the first year
  - Driven by synergies and intended \$500 million share buyback as soon as possible post-closing
  
- Highly flexible capital structure and significant cash flow generation for growth reinvestments and return of capital to shareholders
  - Continued reinvestment into the business in high ROI projects
  - Broadened M&A scope and priority
  - Expected to maintain DENTSPLY's current dividend level of \$0.29 per share
  - Anticipated additional ongoing share buybacks

---

**Jeffrey T. Slovin,**

*Chief Executive Officer of DENTSPLY SIRONA*

---



- President and CEO of Sirona since February 2013 and Director since 1999
- Held various senior positions within Sirona, including: President from September 2010 to February 2013, EVP and COO of U.S. Operations from June 2006 until September 2010
- President and CEO of Schick Technologies from June 2004 through June 2006 and President and COO from December 1999 until June 2006

**Christopher T. Clark,**

*President and Chief Operating Officer, Technologies*

---



- President of DENTSPLY since 2009 and CFO since 2013
- Held various senior positions within DENTSPLY from 2003 through 2013, including: COO, Executive Vice President, & Senior Vice President
- Has been employed at DENTSPLY since 1992

---

**Bret W. Wise,**

*Executive Chairman of the Board of DENTSPLY SIRONA*

---



- Chairman of the Board and CEO of DENTSPLY since January 2007
- Held various senior positions within DENTSPLY, including: President and COO in 2006, EVP in 2005, SVP and CFO from December 2002 through December 2004

---

**James G. Mosch,**

*President and Chief Operating Officer, Dental and Healthcare Consumables*

---



- EVP and COO of DENTSPLY since April 2013
- Held various senior positions within DENTSPLY from 2003 through 2013, including: Executive Vice President and Senior Vice President
- Has been employed at DENTSPLY since 1994

---

**Ulrich Michel,**

*Executive Vice President and Chief Financial Officer*

---



- EVP and CFO of Sirona since October 2013
- CFO of WABCO from April 2005 through October 2013
- Preceded by 10 years of financial leadership experience at American Standard and Honeywell/Allied Signal

- Subject to customary closing conditions and regulatory approvals including:
  - DENTSPLY and Sirona stockholder approval
  - Antitrust and competition law approvals
  
- Expected to close in the 1<sup>st</sup> Quarter of Calendar Year 2016
  
- Transition planning activities to begin immediately



*Combined Net Revenue of ~\$3.8bn<sup>1</sup> and Adjusted EBITDA of >\$900mm<sup>1</sup>*

- **Creates the largest global manufacturer of professional dental products and technologies with a world-class sales and service infrastructure**
- **Combination of leading platforms in consumables, equipment and technology creates complementary end-to-end solutions to meet customer needs**
- **Strong culture of innovation and enhanced R&D capabilities will drive the development of better, faster and safer solutions to advance patient care**
- **Better positioned to capitalize on key industry trends to drive growth**
- **\$125+ million of annual pre-tax synergies by year 3, driving robust cash flow for growth reinvestments and return of capital to shareholders**
- **Accretive to both sets of shareholders within the first year**

(1) LTM statistics as of 6/30/15 and excludes revenue from precious metals

### **FOR DENTSPLY:**

#### **Investors:**

##### **Derek Leckow**

*VP, Investor Relations*

DENTSPLY International Inc.

Tel: +1 (717) 849-7863

E-mail: derek.leckow@dentsply.com

#### **Media:**

##### **Michael Freitag / Tim Lynch**

*Partner / Partner*

Joele Frank

Tel: +1 (212) 355-4449

E-mail: mfreitag@joelefrank.com or  
tlynch@joelefrank.com

### **FOR SIRONA:**

#### **Investors:**

##### **Joshua Zable**

*VP, Investor Relations*

Sirona Dental Systems Inc.

Tel: +1 (718) 482-2184

E-mail: joshua.zable@sirona.com

#### **Media:**

##### **Chuck Dohrenwend**

*Managing Director*

Abernathy MacGregor Group

Tel: +1 (212) 371-5999

E-mail: cod@abmac.com